Abstract
Aims: Cerebral sinus venous thrombosis (CSVT) is a potentially life-threatening disease causing 13–22% of all strokes in childhood, in two thirds associated with infection (mainly ENT infection). Clinical manifestations may be subtle and diagnosis delayed because of the wide spectrum of clinical signs. In adults, the first line treatment is anticoagulation – i.v. heparin or LMWH – based on controlled trials. Randomised controlled trials focusing on therapeutic guidelines for children with CSVT are still lacking. Actually recommendations for AC are given considering literature analysis, mainly based on study results in adults.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
